BC-DXI-843 is an AIMP2-DX2 inhibitor with IC50 value of 0.92μM. It demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | AIMP2-DX2, a splicing variant of AIMP2, is up-regulated in lung cancer, possesses oncogenic activity, and results in tumorigenesis. BC-DXI-843 is a potent and selective AIMP2-DX2 inhibitor with an IC50 value of 0.92 μM which is more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. In H460 cells, BC-DXI-843 exhibited dose-dependent inhibition of DX2 protein levels, and it efficiently induced degradation of DX2 at a very low concentration of 1.20 μM. Moreover, BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer[1]. |
作用机制 | BC-DXI-843 was positioned very close to L80, T82, F116, T117, and K129 and it forms two hydrogen bonds with the hydrophobic pocket via T82 and D52[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.83mL 0.37mL 0.18mL |
9.15mL 1.83mL 0.91mL |
18.29mL 3.66mL 1.83mL |
CAS号 | 2421117-98-6 |
分子式 | C28H26N4O4S2 |
分子量 | 546.66 |
别名 | |
运输 | 蓝冰 |
存储条件 |
粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 250 mg/mL(457.32 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |